Literature DB >> 15281340

Role of regulatory factors in pituitary tumour formation.

Marta Korbonits1, Damian G Morris, Alexandra Nanzer, Blerina Kola, Ashley B Grossman.   

Abstract

The molecular basis of pituitary tumorigenesis remains controversial, but there are two major theories which have been subject to most investigation: hormonal (usually hypothalamic factors) and/or growth factor overstimulation, or a molecular defect within the pituitary itself. It has been shown, for example, that excessive regulatory hormone stimulation can lead to an increased number of cells in the pituitary in various physiological or pathological states such as pregnancy (lactotrophs), untreated primary hypothyroidism (thyrotrophs and lactotrophs),primary hypoadrenalism (corticotrophs) and ectopic GHRH-secreting tumours (somatotrophs). Animal models also provide data that in the presence of excessive hypothalamic hormone stimulation, adenoma formation can occur. However, evidence in favour of the monoclonal nature of pituitary tumours argues for an intrinsic molecular defect as the primary initiating event in tumour formation. We review the various hormonal factors and their receptors effecting the different types of pituitary cells, such as CRH, AVP and cortisol feedback on corticotrophs; GHRH, Galpha PKA, somatostatin and GH and IGF feedback on somatotrophs; GnRH, LH/FSH, activin and oestrogen feedback on gonadotrophs; dopamine, oestrogen and prolactin feedback on lactotrophs; and TRH, TSH and thyroid hormone feedback on thyrotrophs. The monoclonal origin of adenomas makes it unlikely that hypothalamic factors could initiate pituitary transformation, but they could still create an environment where there is a higher chance that a possible causative tumorigenic mutation may occur in one (or several) of the overstimulated pituitary cells, or enhance the proliferation of an already-mutated cell.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15281340     DOI: 10.1159/000079038

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  6 in total

Review 1.  Paracrinicity: the story of 30 years of cellular pituitary crosstalk.

Authors:  C Denef
Journal:  J Neuroendocrinol       Date:  2008-01       Impact factor: 3.627

2.  Arc and resistance welding and tumours of the endocrine glands: a Swedish case-control study with focus on extremely low frequency magnetic fields.

Authors:  N Håkansson; C Stenlund; P Gustavsson; C Johansen; B Floderus
Journal:  Occup Environ Med       Date:  2005-05       Impact factor: 4.402

3.  CRH inhibits NF-kappa B signaling in human melanocytes.

Authors:  Blazej Zbytek; Lawrence M Pfeffer; Andrzej T Slominski
Journal:  Peptides       Date:  2006-09-07       Impact factor: 3.750

Review 4.  Treatment of pituitary tumors: dopamine agonists.

Authors:  Gabriella Iván; Nikoletta Szigeti-Csúcs; Márk Oláh; György M Nagy; Miklós I Góth
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

5.  Genetic interaction between the homeobox transcription factors HESX1 and SIX3 is required for normal pituitary development.

Authors:  Carles Gaston-Massuet; Cynthia L Andoniadou; Massimo Signore; Ezat Sajedi; Sophie Bird; James M A Turner; Juan Pedro Martinez-Barbera
Journal:  Dev Biol       Date:  2008-08-18       Impact factor: 3.582

6.  Neuromedins U and S involvement in the regulation of the hypothalamo-pituitary-adrenal axis.

Authors:  Ludwik K Malendowicz; Agnieszka Ziolkowska; Marcin Rucinski
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-05       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.